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There is accumulating evidence suggesting that most leukemia 
is initiated by rare cancer stem cells, referred to as leukemic stem 
cells (LSCs). LSCs are functionally defined as cells able to gener-
ate leukemia upon transfer to an appropriate host (1). Two fun-
damental and interrelated properties of LSCs are the capacity for 
self-renewal and clonal dominance. Clonal dominance refers to the 
clonal expansion of LSCs within the bone marrow microenviron-
ment at the expense of normal hematopoietic cells.
The mechanisms by which mutations and/or epigenetic 
changes that accumulate during leukemogenesis contribute to 
clonal dominance of LSCs are largely unknown. On a functional 
level, acquisition of clonal dominance represents a competitive 
advantage in the bone marrow microenvironment, as suggested 
by stochastic models (2). A requisite property for clonal domi-
nance is the ability to self-renew. The capacity for self-renewal 
can be achieved either by transformation of HSCs with inherent 
self-renewal capacity or by the acquisition of this ability in com-
mitted progenitor populations during leukemogenesis (3). The 
molecular pathways that confer clonal dominance have been 
largely unexplored, though a recent study utilizing retroviral 
mutagenesis showed that the majority of retroviral integrations 
associated with clonal dominance (both malignant and nonma-
lignant) occurred near genes involved in the regulation of HSC 
self-renewal, proliferation, or apoptosis (4).
Severe congenital neutropenia (SCN) is a congenital bone mar-
row failure syndrome characterized by severe neutropenia present 
from birth, an arrest of myeloid differentiation at the promyelo-
cyte/myelocyte stage, and a marked propensity to develop acute 
myeloid leukemia (AML) or a myelodysplastic syndrome (MDS) (5, 
6). The cumulative risk of MDS/AML in patients with SCN after 
10 years is 11%–21% (7, 8). Treatment with G-CSF is effective in 
increasing neutrophil counts and preventing infections (9); how-
ever, the quantity and duration of G-CSF treatment are correlated 
with an increased risk of MDS/AML (7, 8).
Nonsense mutations of CSF3R that truncate the distal cyto-
plasmic portion of the G-CSF receptor (G-CSFR) are present in 
approximately 40% of patients with SCN (10). These mutations 
are acquired and strongly associated with the development of 
AML/MDS (10). Expression of mutant G-CSFR in myeloid cell 
lines results in enhanced proliferative and survival signals (11–13). 
Moreover, transgenic mice carrying truncating mutations of Csf3r 
display a hyperproliferative response to G-CSF (14, 15). However, 
these mice do not develop MDS/AML; thus, a causal relationship 
between CSF3R mutations and leukemia has not been established.
In the present study, we investigated the mechanisms by which 
cells containing mutant CSF3R gain clonal dominance in vivo. 
Surprisingly, competitive repopulation studies using HSC from 
targeted transgenic (knockin) mice carrying the Csf3r truncation 
mutation showed no clonal advantage. However, short-term treat-
ment with G-CSF resulted in a marked competitive advantage of 
mutant HSC. We utilized this inducible model to characterize the 
molecular pathways mediating HSC clonal dominance. These 
studies suggest that accentuated Stat5 activation plays a key role in 
establishing clonal dominance by HSC-expressing mutant Csf3R.
Results
The d715 G-CSFR confers a competitive advantage at the HSC level in a 
G-CSF–dependent fashion. We previously described the generation of 
mice carrying a targeted (knockin) mutation of their Csf3r gene 
that is representative of the truncation mutations found in SCN 
(15). Of note, the targeted transgenic (knockin) approach pre-
serves the genomic organization of the Csf3r allele; accordingly, the 
mutant G-CSFR is expressed in a development- and lineage-specif-
ic fashion. These mice, termed “d715 G-CSFR,” have normal basal 
granulopoiesis but exhibit an exaggerated neutrophil response to 
exogenous G-CSF. To examine the effect of the d715 G-CSFR on 
HSC function, a competitive repopulation assay was performed. 
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Recipient mice were reconstituted with a 1:1 ratio of d715 G-CSFR 
and wild-type bone marrow cells, and the contribution of d715 
G-CSFR cells to hematopoiesis was determined by flow cytom-
etry. At 6 months after transplantation, the contribution of d715 
G-CSFR cells to the neutrophil, B lymphocyte, T lymphocyte, and 
monocyte lineages in the blood was near the predicted 50% level, 
indicating that the d715 G-CSFR does not confer a competitive 
advantage (Figure 1A).
In patients with SCN, the systemic level of G-CSF is high, either 
because of increased endogenous production or its pharmaco-
logic administration (16). To simulate this increase in systemic 
G-CSF, we treated the chimeric mice with G-CSF (10 μg/kg/d) for 
3 weeks and repeated the chimerism analysis (Figure 1, B and C). 
After G-CSF treatment, nearly all of the circulating neutrophils 
were derived from d715 G-CSFR cells (saline, 55.5% ± 4.4% versus 
G-CSF, 97.6% ± 1.2%; P < 0.001). Likewise, nearly all (98.6% ± 0.7%) 
of Gr-1+ granulocytic cells in the bone marrow were of d715 
G-CSFR origin after G-CSF treatment. A significant increase in the 
contribution of d715 G-CSFR cells to the B lymphocyte lineage in 
the bone marrow also was observed (saline, 61.2% ± 6.4% versus 
G-CSF, 89.1% ± 5.7%; P < 0.001); the lack of significant increase in 
circulating B or T lymphocytes after only 3 weeks of G-CSF treat-
ment likely reflects the long half-life of these cells.
The increase in d715 G-CSFR chimerism in the B lymphocyte 
lineage raised the possibility that the d715 G-CSFR confers a 
competitive advantage at the HSC level after G-CSF treatment. To 
address this possibility, chimerism in c-kit+Sca+lineage– (KSL) cells, 
a cell population enriched in HSCs, was assessed. In saline-treated 
mice, the percentage of KSL cells derived from d715 G-CSFR cells 
was 53.3% ± 11.5% (Figure 2). After 3 weeks of G-CSF treatment, 
this percentage increased to 97.8% ± 0.8% (P < 0.001). We next 
asked whether short-term (3-week) treatment with G-CSF results 
in durable increases in d715 G-CSFR chimerism. A separate cohort 
of chimeric mice was generated by transplanting equal numbers of 
wild-type and d715 G-CSFR bone marrow cells into recipient mice. 
Five months after transplantation, these mice were treated for 
3 weeks with G-CSF or saline and then followed for an additional 
3 months. As expected, immediately after G-CSF treatment, virtu-
Figure 1
The d715 G-CSFR confers a competitive repopulation advantage that is dependent upon exogenous G-CSF administration. Irradiated synge-
neic mice were reconstituted with a 1:1 ratio of d715 G-CSFR (Ly5.2+) and wild-type (Ly5.1+) bone marrow cells. (A) The percentage of blood 
neutrophils (Gr-1), B lymphocytes (B220), T lymphocytes (CD3), and monocytes (F4/80) that were derived from d715 G-CSFR (d715) cells is 
shown (n = 9). (B and C) The mice were then treated with G-CSF (10 μg/kg/d; n = 5) or saline alone (n = 4) for 21 days and the contributions of 
d715 G-CSFR cells in the blood (B) and bone marrow (C) were measured. Data represent the mean ± SEM. *P < 0.05.
Figure 2
The contribution of d715 G-CSFR cells to the KSL cell compartment is increased after G-CSF treatment. Chimeric mice generated as described 
in Figure 1 were treated with saline or G-CSF (10 μg/kg/d) for 21 days, and the percentage of KSL cells in the bone marrow derived from d715 
G-CSFR cells was determined. (A) Representative scatter plot showing the strategy to identify KSL cells (boxed); data are gated on lineage– cells 
(data not shown). (B) Representative scatter plots gated on KSL cells showing the percentage of d715 G-CSFR (Ly5.2+) cells. (C) The percent-
age of KSL cells derived from d715 G-CSFR cells is shown (n = 4–5 each). Data represent the mean ± SEM. *P < 0.001.
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ally all of the circulating neutrophils were of d715 G-CSFR origin 
(Figure 3A). This increase persisted 3 months after discontinuing 
G-CSF treatment; the percentage of circulating neutrophils derived 
from d715 G-CSFR cells was 69.2% ± 3.28% versus 47.3% ± 2.07% 
for saline-treated mice (P < 0.001). Strikingly, G-CSF treatment 
also significantly increased the contribution of d715 G-CSFR cells 
to the B lymphocyte lineage. Three months after discontinuing 
G-CSF, the percentage of circulating B lymphocytes derived from 
d715 G-CSFR cells was 76.6% ± 1.98% versus 56.9% ± 2.35% for 
saline-treated mice (P < 0.001).
A defining feature of HSC is their ability to support multilineage 
long-term engraftment after transplantation into recipient mice. 
Consequently, we transplanted bone marrow from chimeric mice 
after treatment with G-CSF or saline into secondary recipient mice, 
and d715 G-CSFR chimerism was assessed 4 months after trans-
plantation. A significant increase in d715 G-CSFR contribution 
to circulating neutrophils (66.9% ± 3.68% versus 32.8% ± 6.09%; 
P < 0.001) and B lymphocytes (76.8% ± 3.90% versus 43.7% ± 6.36%; 
P < 0.001) was detected in secondary recipients that had received 
G-CSF treated bone marrow (Figure 3C). Collectively, these data 
show that the d715 G-CSFR confers a strong competitive advan-
tage to HSC in a G-CSF–dependent fashion.
G-CSF–induced proliferation is increased in d715 G-CSFR HSCs. The 
clonal advantage of d715 G-CSFR HSCs suggested that prolifera-
tion, survival, and/or self-renewal were enhanced. To character-
ize the effect on proliferation, wild-type or d715 G-CSFR mice 
were treated with a single dose of G-CSF, and 24 hours later, the 
cell cycle status of KSL cells in the bone marrow was measured 
(Figure 4). At baseline, a similar percentage of KSL were in the 
S/G2/M phases of the cell cycle (wild type, 8.9% ± 2.0% versus d715 
G-CSFR, 10.0% ± 3.0%; P = NS). After treatment with G-CSF, the 
percentage of cycling KSL cells increased significantly in d715 
G-CSFR mice (34.4% ± 2.4%), with a trend to increased cycling 
in wild-type KSL cells (20.0% ± 3.8%). Of note, G-CSF induced a 
significantly greater proliferative response in d715 G-CSFR com-
pared with wild-type KSL cells (P < 0.05).
The KSL cell population is heterogeneous, containing both HSCs 
and lineage-committed progenitors. Consequently, we repeated 
these experiments using more restrictive criteria to identify HSCs. 
Specifically, we determined the fraction of CD150+CD48–CD41–
lineage– cells that labeled with BrdU in vivo after G-CSF treatment. 
A previous study showed that 1 in 2.2 of these cells has long-term 
repopulating activity (17). Consistent with this study, the fre-
quency of CD150+CD48–CD41–lineage– cells in the bone marrow 
of wild-type mice was approximately 0.005% (Figure 4C). A similar 
frequency was observed in d715 G-CSFR mice and did not change 
with G-CSF treatment (data not shown). In wild-type mice, G-CSF 
treatment had no effect on BrdU incorporation of CD150+CD48–
CD41–lineage– cells (Figure 4D). In contrast, in d715 G-CSFR mice, 
G-CSF treatment significantly stimulated BrdU incorporation 
in these cells (saline, 15.4% ± 7.6% versus G-CSF, 42.8% ± 12.9%; 
P = 0.004). Together, these data suggest that proliferative signaling 
in HSC is greatly enhanced by the d715 G-CSFR.
Short-term G-CSF treatment induces the activation of Stat3 and/or Stat5 
target genes in KSL cells. To elucidate the molecular mechanisms by 
which the d715 G-CSFR confers a clonal HSC advantage, RNA 
expression profiling experiments were performed. Specifically, 
wild-type or d715 G-CSFR mice were treated with a single dose 
of G-CSF or saline, and 3 hours later KSL cells were sorted from 
the bone marrow by flow cytometry. The 3-hour time point was 
chosen to identify early transcriptional targets of G-CSF signal-
ing in KSL cells. Of note, this brief exposure to G-CSF had no 
discernible effect on KSL number or flow cytometry characteris-
tics (data not shown). Data from 3 independent experiments were 
pooled; genes that were consistently upregulated or downregulat-
ed by G-CSF treatment are summarized in Supplemental Tables 
1 and 2 (supplemental material available online with this article; 
doi:10.1172/JCI32704DS1). Two criteria were used to identify 
genes differentially regulated by G-CSF in d715 G-CSFR KSL cells. 
First, genes were selected in which the magnitude of the change 
in mRNA expression after G-CSF treatment in d715 G-CSFR KSL 
cells was at least 2.0-fold greater than that observed with wild-type 
KSL cells. Second, a significant difference in the absolute gene 
chip signal between G-CSF–treated wild-type and d715 G-CSFR 
KSL cells was required. Based on these criteria, 14 genes were 
identified (Table 1). Strikingly, there is evidence that Stat3 
and/or Stat5 regulate the mRNA expression of 6 of these genes, 
including Sprr2a (18), Tcrg (19, 20), Pim2 (21), Cdkn1a (22, 23), 
Figure 3
Long-term d715 G-CSFR chimerism following G-CSF treatment is increased. Chimeric mice generated as described in Figure 1 were treated 
5 months after bone marrow transplantation (BMT) with saline alone or G-CSF (10 μg/kg/d) for 21 days (indicated by the gray box). The percent-
age of circulating neutrophils (A) and B lymphocytes (B) derived from d715 G-CSFR cells was determined at the indicated times (n = 6–7 for each 
group). (C). Bone marrow was harvested from chimeric mice after treatment with G-CSF or saline and transplanted into secondary recipients 
(n = 5–10 each cohort of recipient mice). Shown is the percentage of d715 G-CSFR cells in the blood of the secondary recipients 4 months after 
transplantation. Data represent the mean ± SEM. *P < 0.001.
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Cish (24), and Socs2 (25). These data suggest the hypothesis that 
accentuated activation of Stat3 and/or Stat5 mediates the HSC 
clonal advantage of the d715 G-CSFR.
Stat5 but not Stat3 activation by G-CSF is accentuated in d715 G-CSFR 
KSL cells. A flow cytometric assay to quantify the phosphoryla-
tion of Stat3 and Stat5 was used to assess the activation of these 
proteins in KSL cells (26). We first validated the assay in primary 
murine myeloid cells (Figure 5, A and B). Consistent with previous 
studies utilizing gel shift assays (12, 27), Stat5 activation by the 
d715 G-CSFR in primary myeloid cells was markedly enhanced 
(AUC: wild type, 148 ± 28 and d715 G-CSFR, 371 ± 86; P < 0.05). 
Again, consistent with previous reports (12, 27), Stat3 activa-
tion in d715 G-CSFR myeloid cells, though delayed, was compa-
rable with wild-type cells (AUC: wild type, 2,053 ± 546 and d715 
G-CSFR, 2,711 ± 815; P = NS).
Similar experiments were performed with KSL cells (Figure 5, 
C and D). Compared with wild-type cells, both the magnitude 
and duration of Stat5 activation by G-CSF was increased in 
d715 G-CSFR cells (AUC: wild type, 203 ± 73 and d715 G-CSFR, 
771 ± 187; P = 0.05). In contrast, Stat3 activation by G-CSF in 
d715 G-CSFR KSL cells was significantly reduced at early time 
points after G-CSF stimulation (Figure 5D), with a trend to a 
decrease in overall Stat3 activation (AUC: wild type, 1,315 ± 491 
and d715 G-CSFR, 1,020 ± 530; P = 0.16). These data show that 
Stat5 activation by the d715 G-CSFR in KSL cells was enhanced, 
whereas Stat3 activation was attenuated.
The hyperproliferative response of the d715 G-CSFR is abrogated in Stat5-
deficient myeloid progenitors. We next sought to assess the effect of 
the loss of Stat5 on the clonal dominance conferred by the d715 
G-CSFR. However, the engraftment potential of Stat5A–/– × Stat5B–/– 
HSC is markedly impaired (28, 29), precluding the direct assess-
ment of the d715 G-CSFR on HSC function in Stat5-deficient 
cells. Instead, we determined whether the previously described 
hyperproliferative phenotype conferred by the d715 G-CSFR on 
myeloid progenitors is abrogated by Stat5 deficiency. In brief, 
hematopoietic cells harvested from the fetal liver of wild-type or 
Stat5A–/– × Stat5B–/– mice were transduced with retrovirus express-
ing wild-type or d715 G-CSFR and colony formation in response 
to G-CSF measured. As reported previously, expression of the d715 
G-CSFR in Stat5-sufficient cells resulted in a significant increase 
in both colony number and average colony size (Figure 6, A and B). 
In Stat5A–/– × Stat5B–/– cells, G-CSF–induced colony formation 
was reduced, and the hyperproliferative response conferred by the 
d715 G-CSFR was abrogated.
Figure 4
G-CSF–induced proliferation of d715 G-CSFR HSCs is increased. Wild-type or d715 G-CSFR mice were treated with saline or G-CSF (2 doses of 
100 μg/kg, 12 hours apart); in some cases (C and D), mice also received BrdU (2 doses of 1 mg, 12 hours apart). (A) Representative histograms 
showing Hoechst staining of KSL cells. (B). Shown is the percentage of KSL cells in the S/G2/M phases of the cell cycle (n = 3–4 per condition). 
(C) Representative scatter plots showing the gating strategy and BrdU staining of CD150+CD48–CD41–lineage– cells. (D) Shown is the percent-
age of CD150+CD48–CD41–lineage– cells that labeled with BrdU (n = 5–6 per condition). Data represent the mean ± SEM.
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Loss of Stat3 and Stat5 activation by the d715F G-CSFR is associated with 
decreased HSC function. To further test the hypothesis that Stat3 
and/or Stat5 activation mediates the clonal HSC advantage of the 
d715 G-CSFR, we next studied d715F G-CSFR–targeted transgenic 
(knockin) mice. In the d715F G-CSFR mutant, the sole remaining 
tyrosine (Y704) of d715 G-CSFR is mutated to phenylalanine. We 
previously showed that Stat3 and Stat5 activation by the d715F 
G-CSFR in primary murine myeloid cells is markedly impaired (27). 
Similar results were obtained with KSL cells (Figure 7, A and B). 
In fact, no detectable Stat5 or Stat3 activation was observed in 
d715F KSL cells following G-CSF stimulation.
To determine whether the loss of Stat3 and Stat5 activation by 
the d715F G-CSFR affected HSC function, we repeated the com-
petitive repopulation assay using a 1:1 ratio of d715F G-CSFR and 
wild-type bone marrow cells. Consistent with the known defect 
in granulopoiesis in d715F G-CSFR mice (27), the contribution 
of d715F G-CSFR cells to the neutrophil lineage was consistently 
less than that observed in the B or T lymphocyte lineages (Figure 7, 
C–E). Chimeric mice were treated with G-CSF for 3 weeks starting 
4 months after transplantation. Despite the loss of Stat3 and Stat5 
activation, a significant increase in d715F G-CSFR chimerism in 
the neutrophil lineage was observed. However, this increase was 
transitory, returning to control levels after stopping the G-CSF. In 
fact, a gradual decrease in d715F G-CSFR contribution to neutro-
phils, B lymphocytes, and T lymphocytes was observed over time, 
irrespective of whether G-CSF was given. These data suggest that 
the d715F G-CSFR confers a competitive disadvantage to HSC.
Discussion
Truncation mutations of CSF3R are strongly and uniquely asso-
ciated with the development of MDS/AML in patients with SCN. 
Whereas truncation mutations of CSF3R are present in 78% of 
cases of MDS/AML in patients with SCN (10), they are observed 
in only 1%–2% of de novo AML cases (10, 30, 31). These muta-
tions are acquired and achieve clonal dominance in the human 
bone marrow microenvironment. In the present study, we show 
that expression of a representative G-CSFR truncation mutant 
confers a strong clonal advantage at the HSC level. However, 
the clonal dominance is dependent upon exogenous G-CSF 
administration; similar results were observed after treating mice 
for 3 weeks with 2 different doses of G-CSF: 10 μg/kg/d and 
100 μg/kg/d (data not shown). The requirement for high system-
ic levels of G-CSF may explain the unique association of CSF3R 
mutations with SCN, since in SCN, systemic levels of G-CSF are 
high due to increased endogenous production or pharmacologic 
administration (16). A novel feature of this model is the induc-
ibility of the HSC clonal dominance, providing a tool to explore 
molecular mechanisms for this process.
There is increasing evidence that HSC quiescence is associated 
with long-term repopulating activity. Transplantation studies of 
phenotypically defined HSC fractionated based on cell cycle have 
shown that the quiescent fraction has the highest repopulating 
activity (32, 33). Moreover, loss-of-function mutations for Cdkn1a 
(p21waf1) (34) or Pten (35, 36) that result in excessive HSC prolifera-
tion are associated with loss of long-term repopulating ability. In 
contrast, in the present study, we show that mutant Csf3r confers 
increased repopulating activity despite inducing greater prolifera-
tion of HSC (as defined by KSL or CD150+CD41–CD48–lineage– 
cells). These observations suggest the possibility that the nature 
of the proliferative signals generated by mutant Csf3r may pre-
serve the long-term repopulating activity of HSC. In this regard, 
it is interesting to note that Cdkn1a (p21waf) expression is strongly 
induced by G-CSF in Csf3r mutant HSC (Table 1). As noted above, 
Cdkn1a is a negative regulator of HSC proliferation and helps 
maintain HSC quiescence. Thus it is possible that simultaneous 
induction of proliferative signals and Cdkn1a expression may pre-
vent the loss of long-term repopulating activity associated with 
uncontrolled HSC proliferation.
There is considerable evidence linking Stat5 to the regulation 
of HSC function. Stat5 is activated by several cytokine receptors 
implicated in the regulation of HSC, including MPL and FLT3 
(37, 38). Moreover, loss of function mutations for both Stat5A 
and Stat5B lead to a profound defect in hematopoietic repopulat-
ing activity (28, 29, 39). Conversely, expression of a constitutively 
active form of Stat5 in both murine and human hematopoietic 
progenitors promoted the self-renewal and expansion of multi-
Table 1
RNA expression profiling
	 	 WT	 	 	 d715	G-CSFR
Gene	 Saline	 G-CSF	 Fold	change	 Saline	 G-CSF	 Fold		change	 RatioA	 P	valueB
Tcrg  318 ± 91 202 ± 88 0.64 266 ± 24 2,492 ± 438 9.37 14.7 <0.005
Sprr2a 810 ± 124 2,098 ± 903 2.59 599 ± 122 21,072 ± 6,628 35.2 13.6 <0.05
Tnfsf11 435 ± 116 251 ± 95 0.58 232 ± 108 1,116 ± 74 4.81 8.34 <0.005
Cish 2,730 ± 525 3,005 ± 110 1.10 2,829 ± 801 13,794 ± 556 4.88 4.43 <0.0005
Pim2 1,382 ± 293 1,981 ± 530 1.43 1,040 ± 326 6,337 ± 1,523 60.09 4.25 <0.05
Enah 230 ± 83 1,495 ± 127 6.50 628 ± 203 17,320 ± 2,265 27.6 4.24 <0.005
Zfpn1a4 167 ± 68 181 ± 68 10.08 248 ± 92 1,105 ± 76 4.46 4.11 <0.0005
Socs2 903 ± 62 1,315 ± 335 1.46 2,210 ± 868 11,020 ± 1,488 4.99 3.42 <0.005
Cdkn1a 987 ± 171 1,541 ± 206 1.56 791 ± 135 4,057 ± 568 5.13 3.29 <0.01
Serpina3g 22,519 ± 5,363 31,260 ± 4,761 1.39 20,302 ± 5,034 83,742 ± 13,422 4.12 2.97 <0.05
Bcat1 137 ± 49 572 ± 95 4.18 75 ± 34 883 ± 46 11.8 2.82 <0.05
Cacnb2 769 ± 769 1,621 ± 77 2.11 585 ± 277 3,018 ± 595 5.16 2.45 <0.05
Ltb4r1 1,025 ± 259 730 ± 198 0.71 3,231 ± 2,069 276 ± 34 0.09 0.12 <0.05
Bhlhb2 127 ± 52 1,267 ± 179 9.98 723 ± 583 2,501 ± 133 3.46 0.35 <0.005
The mean ± SEM raw signal of experiments performed in triplicate is shown. ARatio of the fold change after G-CSF treatment between wild-type and d715 
G-CSFR cells. BComparing G-CSF–treated wild-type KSL cells with G-CSF–treated d715 G-CSFR KSL cells.
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potential progenitors ex vivo (37, 40). Herein, we show that Stat5 
but not Stat3 phosphorylation by G-CSF is accentuated in Csf3R 
mutant KSL cells. Accordingly, several well-known Stat5 target 
genes, including PIM2 and Cdkn1a, are induced to a greater degree 
by G-CSF in Csf3R mutant compared with wild-type KSL cells. 
Moreover, though the severe repopulating defect of Stat5A–/– × 
Stat5B–/– cells precluded a direct measure of HSC activity, we show 
that the proliferative advantage of myeloid progenitors expressing 
mutant (d715) Csf3R is dependent upon Stat5. Finally, to directly 
assess the importance of Stat5 activation by G-CSF in the regula-
tion of HSC function, we characterized the long-term repopulating 
activity of HSCs expressing a mutant (d715F) Csf3R engineered to 
have impaired Stat5 activation. In fact, the competitive repopulat-
ing activity of d715F HSCs was reduced compared with wild-type 
HSCs. A caveat of this experiment is that other signaling pathways 
besides Stat5 (and Stat3) may be disrupted by the d715F mutation. 
Collectively, these data suggest that accentuated Stat5 activation 
by mutant Csf3r mediates the clonal HSC advantage.
Stat5 has been implicated in leukemogenesis. Constitutive Stat5 
activation has been detected in approximately 25% of leukemias 
(41), and it is specifically associated with leukemias carrying inter-
nal tandem duplications of FLT3 (FLT3 ITD) (42). Expression of 
constitutively active Stat5 in hematopoietic cells results in a rap-
idly fatal myeloproliferative disease in mice (37, 41, 43). Studies 
of Stat5A × Stat5B doubly deficient 
mice have suggested an obligatory 
role for Stat5 in leukemogenesis 
induced by BCR-ABL and TEL-
JAK2 (43, 44). Moreover, a recent 
study showed that RNAi-mediated 
inhibition of STAT5 expression 
in human leukemic progenitors 
inhibited their long-term growth 
in vitro (45). Our data provide fur-
ther support for a key role for Stat5 
in leukemogenesis. Specifically, 
our data suggest that Stat5 activa-
tion may contribute to the acquisi-
tion of clonal dominance by LSCs. 
However, Stat5 activation alone 
does not appear to be sufficient to 
induce leukemia, since we previous-
ly showed that d715 G-CSFR mice 
did not develop leukemia despite 
chronic (6-month) treatment with 
G-CSF (15).
The Stat5 target genes that regu-
late HSC function and confer clon-
al dominance have not yet been 
determined. A number of genes 
have been implicated in the regula-
tion of HSC self-renewal, includ-
ing Bmi1 (46), HoxB4 (47), Mef 
(48), Tie2 (49), Catnb (50), CEBPA 
(51), Cdkn2c (p18INK4c) (52), Notch1, 
Notch4 (53), Gfi1 (54, 55), and Nfya 
(56). However, none of these genes 
were significantly upregulated in 
vivo in KSL cells after 3 hours of 
G-CSF stimulation (data not 
shown). Studies are underway to see whether any of these genes 
are activated at later time points after G-CSF stimulation. Of the 
genes differentially regulated by G-CSF in Csf3r mutant KSL cells 
(Table 1), several have been implicated in the regulation of HSC 
function or leukemogenesis. As already discussed, Cdkn1a has been 
shown to regulate HSC self-renewal (34). Pim2 is a serine-threonine 
kinase that has been shown to play a pivotal role in the transmis-
sion of proliferative and survival signals by FLT3 ITD (47, 57). The 
importance of these genes is currently being investigated through 
the use of the relevant loss-of-function transgenic mice.
The high rate of leukemic transformation in SCN, and the dis-
mal prognosis once MDS or AML develops, has led to considerable 
debate over the timing of allogeneic HSC transplantation (HSCT) 
in patients with SCN. Unfortunately, there are no randomized clini-
cal trials comparing HSCT with standard therapy in SCN. However, 
based on its strong association with MDS/AML, the presence of 
CSF3R mutations has been proposed as an indication for HSCT, 
even in the absence of MDS/AML (10). The present study supports 
this approach. Though none of the Csf3r mice developed MDS/
AML, our data showing that the mutant Csf3r confers a clonal HSC 
advantage increases the likelihood that CSF3R mutations contrib-
ute to leukemic transformation. Alternatively, the dependence of 
the HSC clonal advantage on high systemic levels of G-CSF sug-
gests that discontinuing G-CSF administration may result in the 
Figure 5
Stat5 but not Stat3 activation by G-CSF is enhanced in d715 G-CSFR cells. Wild-type or d715 G-CSFR 
bone marrow cells were treated in vitro for the indicated times with G-CSF (100 ng/ml), and the cells 
were then incubated with antibodies specific for phosphorylated Stat5 or Stat3. (A and B) The MFI of 
Gr-1+ (myeloid) cells for pStat5 (A) and pStat3 (B) is shown. (C and D) The MFI of KSL cells for pStat5 
(C) and pStat3 (D) is shown. Data represent the mean ± SEM (n = 4 per cohort). *P < 0.05 compared 
with wild-type cells at the same time point.
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loss (or at least stabilization) of the CSF3R mutant clone. Indeed, 
there is a case report in which a patient with a CSF3R mutation and 
AML had a spontaneous remission of AML after stopping G-CSF 
(58). However, treatment with G-CSF is proven to improve surviv-
al in patients with SCN, and there currently is no other effective 
therapy to increase neutrophil counts in patients with SCN. In the 
absence of such a therapy, it may be prudent to consider allogeneic 
HSCT in all patients with SCN who acquire a CSF3R mutation.
Figure 6
Stat5 deficiency abrogates the hyperproliferative response of the d715 G-CSFR in myeloid progenitors. E12–E15 fetal liver cells from wild-
type or Stat5A–/– × Stat5B–/– (Stat5–/–) mice were transduced with retrovirus expressing neomycin phosphotransferase alone (Neo) or this 
gene and either wild-type G-CSFR (WT GR) or d715 G-CSFR. Cells were cultured in 10 ng/ml of G-CSF and geneticin to select for trans-
duced cells. Shown is the number of colonies (A) and average colony size (B) observed after 7–10 days. Similar results were observed in 
cultures stimulated with 1 ng/ml of G-CSF (data not shown). No colonies formed in the absence of G-CSF (data not shown). Data represent 
the mean ± SEM of 3 independent experiments.
Figure 7
Competitive repopulation by HSC expressing the d715F G-CSFR is impaired. (A and B) Wild-type or d715F G-CSFR KSL cells were treated in 
vitro for the indicated times with G-CSF (100 ng/ml) and then incubated with antibodies specific for pStat5 (A) or pStat3 (B). The MFI of triplicate 
experiments is shown. (C–E) Irradiated syngeneic mice were reconstituted with a 1:1 ratio of d715F G-CSFR and wild-type bone marrow cells. 
The resulting chimeric mice were treated 4 months after bone marrow transplantation with saline alone or G-CSF (10 μg/kg/d) for 21 days. The 
percentage of circulating neutrophils (C), B lymphocytes (D), and T lymphocytes (E) derived from d715F G-CSFR cells was determined at the 
indicated times (n = 3–4 for each group). Data represent the mean ± SEM. *P < 0.05 compared with saline-treated mice.
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Methods
Mice. d715 G-CSRR and d715F G-CSFR mice backcrossed 10 generations 
onto a C57BL/6 background were generated as described previously (15, 
27). C57BL/6 mice (B6.SJL-Ptprc*/Pep3b/BoyJ) that have the Ly5.1 gene 
were obtained from The Jackson Laboratory. Stat5a+/– × Stat5b+/– mice out-
bred on a NIH Black Swiss × 129SvEv × C57BL/6 background were gener-
ated as previously described (59). These mice were intercrossed to generate 
Stat5a–/– × Stat5b–/– fetuses. Mice were housed in a specific pathogen–free 
environment. All experiments were approved by the Washington University 
Animal Studies Committee.
Competitive repopulation assay. Wild-type (Ly5.1), d715, or d715F 
G-CSFR (Ly5.2) bone marrow cells were harvested from strain- and sex-
matched mice. A total of 5 million bone marrow cells were mixed at a 
1:1 ratio and injected into the tail vein of lethally irradiated wild-type 
mice (Ly5.1). Recipient mice were conditioned with 1,000 cGy from 
a 137Cesium source at a rate of approximately 95 cGy/min 24 hours 
prior to transplantation. Prophylactic antibiotics (trimethoprim-sulfa-
methoxazole; Alpharma) were given during the initial 2 weeks following 
transplantation. Mice were analyzed 3–12 months after transplantation. 
Where indicated, mice were treated with human recombinant G-CSF 
(Amgen) in PBS with 0.1% low-endotoxin BSA at a dose of 10 μg/kg/d 
for 21 days. Secondary bone marrow transplantation was performed 
immediately following treatment with G-CSF or saline alone. Bone mar-
row cells (5 × 106) from the primary recipient mice were transplanted 
into secondary recipient mice.
Flow cytometry. Bone marrow and blood leukocytes were processed for 
flow cytometry as previously described (60). For chimerism analysis, cells 
were incubated with FITC-conjugated Ly5.1, Cy5-PE–conjugated Ly5.2, 
and one of the following PE-conjugated lineage markers: Gr-1 (myeloid), 
B220 (B lymphocytes), CD3 (T lymphocytes), or F4/80 (monocytes; Caltag 
Laboratories). Isotype-matched antibodies were used as negative controls. 
Cells were analyzed on a 2-laser, 5-color FACScan flow cytometer (BD Bio-
sciences and Cytek Development). Unless otherwise indicated, all antibod-
ies were obtained from BD Biosciences.
To analyze KSL cells, lineage+ cells were first depleted. In brief, cells were 
incubated with the following PE-conjugated lineage markers: CD3, B220, 
Gr-1, and Ter-119. Following incubation with anti-PE colloid, lineage+ cells 
were depleted using the AutoMacs system (Miltenyi Biotec). The lineage-
depleted cells were then incubated with FITC-conjugated Sca-1, APC-con-
jugated c-kit, Cy5-PE–conjugated Ly5.2, and Cy7-APC–conjugated Ly5.1.
Cell cycle analysis of KSL cells. Following lineage depletion and incubation 
with FITC-conjugated Sca1 and APC-conjugated c-kit, bone marrow cells 
were incubated with 10 μg/ml Hoechst 33342 (Molecular Probes) in PBS 
containing 0.2% BSA at 37°C for 60 minutes. Hoechst staining of the KSL 
cells was assessed using a MoFlo high-speed cell sorter (Dako).
BrdU labeling. Mice (n = 5 per condition) were injected with BrdU (2 doses 
of 1 mg given 12 hours apart; BD Biosciences) and either saline alone of 
G-CSF (2 doses of 100 μg/kg given with the BrdU). Bone marrow cells 
were harvested 12 hours after the final dose of BrdU and incubated with 
FITC-conjugated CD48 (eBioscience) and CD41, biotinylated CD150 
(clone number TC15-12F12.1; Biolegend), and the following panel of Cy5-
PE–conjugated lineage markers: CD3, B220, Gr-1, and Ter-119. Following 
incubation with streptavidin-PE (eBioscience), cells were fixed, permeabi-
lized, and incubated with PE-conjugated anti-BrdU antibody per the man-
ufacturer’s recommendations (BrdU flow kit; BD Biosciences). Cells were 
analyzed using a MoFlo high-speed cell sorter.
Expression profiling and data analysis. Groups of 8–10 wild-type, d715 
G-CSFR, or d715F G-CSFR mice were treated with a single subcutaneous injec-
tion of G-CSF (100 μg/kg) or saline alone. Bone marrow cells were harvested 
3 hours later and KSL cells sorted. RNA was prepared from 20,000–100,000 
KSL cells using Trizol reagent (Invitrogen). Total cellular RNA samples of 
100 ng were subjected to linear amplification, biotin labeling, fragmenta-
tion, and hybridization to Affymetrix MOE430 v2.0 GeneChip microarrays 
per protocols of the Siteman Cancer Center Multiplexed Gene Analysis 
Core Facility (http://pathology.wustl.edu/research/multiplexed.php). 
Experiments were performed in triplicate.
Visualization and statistical analysis of data were performed using Deci-
sion Site (Spotfire). Signal values corresponding to the probesets were nor-
malized to adjust for minor differences in hybridization intensities across 
the 12 microarrays analyzed. After normalization, mean signal intensi-
ties for each probeset were calculated across the 3 experiments. Probesets 
upregulated or downregulated by G-CSF compared with saline control 
were selected based upon the following selection criteria: (a) present detec-
tion call in at least 2 of 3 probesets corresponding to the upregulated 
condition; (b) absolute signal intensity > 500 in at least 2 of 3 probesets 
corresponding to the upregulated condition; and (c) greater than 2-fold 
change in mean signal intensity (hereafter referred to as fold-induction ratio) 
between G-CSF and saline. In cases where multiple probesets corresponded 
to the same gene, the probeset with the highest average signal intensity and 
greatest number of present calls was used.
Assessment of Stat5 and Stat3 phosphorylation by flow cytometry. Bone marrow 
cells were either incubated with FITC-conjugated Gr-1 or lineage depleted 
and then incubated with FITC-Sca1 and APC–c-kit. Cells were then sus-
pended in Opti-MEM (Invitrogen) with 10% FBS and stimulated with 
G-CSF (100 ng/ml) for the indicated time at 37°C. As a control, dupli-
cate samples were cultured without G-CSF. Following incubation, cells 
were incubated in BD Phosphflow Lyse/fix buffer (BD Biosciences) for 
10 minutes, permeabilized in 100% methanol at 4°C for 20 minutes, and 
then incubated with anti-pStat5 (pY694) or anti-pStat3 (pY705) antibody 
(BD Biosciences) at room temperature for 30 minutes.
Retroviral transduction of Stat5a–/– × Stat5b–/– fetal liver progenitors. Stable 
clones of the ecotropic packaging cell line GP+E86 containing the ret-
roviral viral vector pMPncrdleno alone or this vector with cDNAs for 
wild-type murine G-CSFR or the d715 G-CSFR have been previously 
described (61). Cultures of fetal liver cells from 12- to 15-dpc Stat5a–/– × 
Stat5b–/– fetuses were generated as previously described (62). Cells were 
cultured for 24 hours in RPMI containing 10% FBS, 50 ng/ml of murine 
thrombopoietin, 100 ng/ml of murine stem cell factor, 10 ng/ml of 
murine interleukin-3, and 50 ng/ml of human flt3 ligand at 37°C in 
5% CO2 (all cytokines were obtained from Peprotech). Cells were then 
cocultured in the same media with irradiated (1,500 cGy) GP+E86 cells 
for 48 hours. Viable cells (0.5–1 × 105 cells) recovered from these cul-
tures were plated in MethoCult M3231 (Stem Cell Technologies) supple-
mented with 1 or 10 ng/ml of human G-CSF and 1 mg/ml of geneticin 
(Invitrogen). Colonies containing at least 50 cells were scored on days 
7–10 of culture. To determine transduction efficiency, 1–2 × 104 cul-
tured fetal liver cells were placed in MethoCult M3434 with or without 
1 mg/ml of geneticin and the percentage of colonies that were resistant to 
geneticin measured. A similar transduction efficiency (range 30%–52%) 
for all 3 retroviruses with both wild-type and Sta5a–/– × Stat5b–/– cells was 
observed (data not shown).
Statistics. Statistical significance was determined either by a 2-way ANOVA 
analysis or by a 2-sided Student t test. All data represent the mean ± SEM, 
unless otherwise stated.
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